Cargando…

Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Osimertinib (Tagrisso(®)) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mut...

Descripción completa

Detalles Bibliográficos
Autor principal: Scott, Lesley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300577/
https://www.ncbi.nlm.nih.gov/pubmed/30631243
http://dx.doi.org/10.1007/s40267-018-0536-9

Ejemplares similares